Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma

NCT03957551 is registered in ClinicalTrials.gov with John Rieth as lead sponsor.

NCT NCT03957551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03957551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma
Lead sponsor
John Rieth
Phase
Phase 1/2
Overall status
Terminated
Start date
August 27, 2019
Completion date
October 17, 2025
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced metastatic melanoma